# US 2013/0259930 A1 · Compositions and Methods for Preventing and Treating Mucositis and Weight Loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259930 A1
- Document ID: US20130259930A1
- Status: Published application
- Kind: A1
- Application number: 13/899,967
- Filed: 2013-05-22
- Published: 2013-10-03
- Earliest claimed: 2007-03-12
- Assignees: Cascade Estate Ltd.
- Applicants: Cascade Estate Ltd.
- Inventors: Patrick T. Prendergast
- Web page: https://patentgrep.com/patent/US20130259930A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia.

## Claims

### Claim at position 1

1-101. (canceled)

### Claim 102

A pharmaceutical composition comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione(oltipraz) or an analogue, derivative, metabolite, prodrug, solvate or pharmaceutically acceptable salt and a pharmaceutical carrier, which promotes association of the 5-[2-pyrazinyl]-4-methyl-1,2-3-thione(oltipraz) or an analogue, derivative, metabolite, prodrug, solvate or pharmaceutically acceptable salt with the outer wall of a subject's digestive tract.

### Claim 103 (depends on 102)

A pharmaceutical composition of claim 102, wherein the metabolite is pyrrolopyrazine derivative metabolite 3.

### Claim 104 (depends on 102)

A pharmaceutical composition of claim 102, wherein the analogue is anethole trithione ((5-(p-methoxyphenyl)-3H-1,2-dithiole-3-thio).

### Claim 105 (depends on 102)

A pharmaceutical composition of claim 102, which is formulated with carboxymethyl cellulose.

### Claim 106 (depends on 102)

A pharmaceutical composition of claim 102, which is formulated with cysteine or an analogue, derivative, salt or solvate thereof.

### Claim 107 (depends on 102)

A pharmaceutical composition of claim 102, which is formulated with a chemotherapeutic agent.

### Claim 108 (depends on 102)

A pharmaceutical composition of claim 102, which is formulated with a sulphur-containing amino acid.

### Claim 109 (depends on 102)

A method for preventing or treating mucositis in a subject comprising administering to the subject a therapeutically effective amount of a composition of claim 102.

### Claim 110 (depends on 109)

A method of claim 109, wherein the subject is a cancer patient.

### Claim 111 (depends on 109)

A method of claim 109, wherein the cancer patient is undergoing chemotherapy, radiation treatment or a combination thereof.

### Claim 112 (depends on 109)

A method of claim 109, wherein the mucositis is selected from the group consisting of: enteritis, oropharyngeal mucositis, stomatitis and proctitis.

### Claim 113 (depends on 102)

A method for preventing or treating cachexia in a subject comprising administering to the subject a therapeutically effective amount of a composition of claim 102.

### Claim 114 (depends on 113)

A method of claim 113, wherein the subject is a cancer patient.

### Claim 115 (depends on 114)

A method of claim 114, wherein the cancer patient is undergoing chemotherapy or radiation treatment.

### Claim 116 (depends on 109)

A method of claim 109, wherein the administering is oral administration.

### Claim 117 (depends on 109)

A method of claim 109, wherein the composition is administered in the form of an oral rinse, in liquid form, in a capsule, in a tablet, in an injection or as a suppository.

### Claim 118 (depends on 113)

A method of claim 113, wherein the administering is oral administration.

### Claim 119 (depends on 113)

A method of claim 113, wherein the composition is administered in the form of an oral rinse, in liquid form, in a capsule, in a tablet, in an injection or as a suppository.
